Skip to main content

Gary Branning, MBA

President
Managed Market Resources
Mt Olive, NJ
Authored Items
Mental Illness Disclosure in the Workplace: An Opportunity for Improvement
Gary Branning, MBA, Heidi C. Waters, PhD, Christy R. Houle, PhD, MPH, Stacey L. Worthy, Esq, Betsy Fink, MBA, PMP, Katie Hayes
December 2021 Vol 14, No 4 in Clinical, Review Article
Politics and Healthcare: Drug Pricing Dynamics Leading Up to the 2020 Election
Gary Branning, MBA, Kathryn Hayes, BA
October/November 2020 Vol 13, No 5 in Perspectives
Outcomes-Based Contracting for Disease-Modifying Therapies in Multiple Sclerosis: Necessary Conditions for Paradigm Adoption
Cori Gray, PharmD, Gary Branning, MBA, James T. Kenney, RPh, MBA
December 2019 Vol 12, No 8 in Business, Original Research
Value-Based Agreements in Healthcare: Willingness versus Ability
Gary Branning, MBA, Michael Lynch, CPA, MBA, Kathryn Hayes, BA
September 2019 Vol 12, No 5 in Industry Trends
Tumor Necrosis Factor Inhibitor Therapy and the Risk for Depression Among Working-Age Adults with Rheumatoid Arthritis
Arijita Deb, PhD, Nilanjana Dwibedi, BPharm, MBA, PhD, Traci LeMasters, PhD, Jo Ann Hornsby, MD, Wenhui Wei, PhD, Usha Sambamoorthi, PhD, Gary Branning, MBA
February 2019 Vol 12, No 1 in Clinical, Original Research
A Shift in Party Majority, a Shift in Priority? What the Pharmaceutical Industry Can Expect
Gary Branning, MBA, Randy Ross, BA, Kathryn Hayes, BA
February 2019 Vol 12, No 1 in Industry Trends
Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry
Gary Branning, MBA, Dimitrios A. Pappas, MD, Robert A. Gerber, PharmD, MA, MBA, Heather J. Litman, PhD, David Gruben, PhD, Jamie Geier, PhD, Winnie D. Hua, MS, Connie Chen, PharmD, Youfu Li, MD, MPH, Joel M. Kremer, MD, John S. Andrews, MD, Jeffrey A. Bourret, PharmD
May 2018 Vol 11, No 3 in Clinical, Original Research
New Rivals: Integrating Health Benefits to Provide Comprehensive Patient Care
Gary Branning, MBA, Martha Vater
April 2018 Vol 11, No 2 in Industry Trends
Emphasize Shared Decision-Making Between Physicians and Patients to Improve Diabetes Outcomes
Gary Branning, MBA, Stacey L. Worthy, Esq, Martha Vater
July 2017 Vol 10, No 5 in Industry Trends
Multispecialty Rating of Evidence-Based Conditions for Intravenous Immunoglobulin Therapy Using a 3-Axis Prioritization Algorithm
Jordan S. Orange, MD, PhD, Gary Branning, MBA, Matt Johnson, BA, Barbara Lennert, RN, BSN, MAOM, Katarzyna Shields, PharmD, MBA, BCOP, BCPS, Michael Eaddy, PharmD, PhD
May 2017 Vol 10, No 3 in Clinical
Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States
Joseph Lee, PhD, Gary Branning, MBA, Ryan Pelkey, MS, Julieanna Gubitosa, BS, Michael F. Henrick, MBA, Michael L. Ganz, PhD
February 2017 Vol 10, No 1 in Business
Healthcare Spending: Plenty of Blame to Go Around
Gary Branning, MBA, Martha Vater
November 2016 Vol 9, No 8 in Industry Trends
Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD Exacerbation
Gary Branning, MBA, Qing Lee, PhD, Michelle Mocarski, MPH, Shawn X. Sun, PhD
May 2016 Vol 9, No 3 in Clinical
Competition Heats Up in Rheumatoid Arthritis and Other Autoimmune Conditions
Gary Branning, MBA
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors
Lisa M. Bloudek, PharmD, MS, Gary Branning, MBA, Dinara Makenbaeva, MD, MBA, Michael Eaddy, PharmD, PhD
December 2015 Vol 8, No 9 in Business, Original Research
Once-Fatal Conditions Have Become Chronic: Early Trends in the FDA’s 2015 Approvals
Gary Branning, MBA
March 2015, Vol 8, Sixth Annual Payers' Guide in Pipeline, Payers' Guide
Last modified: December 29, 2021